Addressing High Dose Vector Toxicity

Time: 2:30 pm
day: Day Two


  • Immunogenicity of AAV is complex, and mitigation strategies should account for innate, humoral and cellular immune responses
  • Toxicity associated with high vector doses is often linked to immunogenicity
  • Mitigation of high dose toxicity may require a multipronged approach, including engineering of more efficient capsids and transgene cassettes and enabling multiple lower doses of AAV rather than a single large dose